Argenta will apply its integrated medicinal chemistry, assay development and screening capabilities and collaborate with Cellzome's scientists in the search for new disease therapies
Argenta Discovery, a contract drug discovery and respiratory drug development company, has entered into a drug discovery collaboration with Cellzome.
The deal also provides Cellzome with access to Argenta's other integrated scientific disciplines including Adme/PK.
Commenting on the agreement, Chris Ashton, Argenta's CEO, said: "We are delighted that one of Europe's leading biotechnology companies has chosen to work with Argenta.
"This new agreement illustrates Argenta's excellence in providing fully integrated collaborative drug discovery.
"Last year our contract research business revenue grew by over 25% and we have had an excellent start to the new financial year: this being the third collaborative agreement we have signed in the last five months".
Tim Edwards, CEO of Cellzome, added: "We chose to work with Argenta because of the experience of the Argenta team; they can provide us with high quality, reproducible results.
"This collaboration will further extend and compliment our own drug discovery unit and will help us move our projects forwards into the clinic".
Adme/PK is the integrated method by which potential drugs are assessed in terms of their absorption, distribution, metabolism and excretion and pharmacokinetics.
